Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study.
Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y. Nishiwaki S, et al. Among authors: hatta y. Hemasphere. 2023 Jun 8;7(6):e899. doi: 10.1097/HS9.0000000000000899. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37475881 Free PMC article. No abstract available.
Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Kimura SI, Shimizu H, Miyazaki T, Sakurai M, Tanoue S, Kayamori K, Ohwada C, Yoshimura K, Nakasone H, Ohashi T, Shono K, Tachibana T, Hatano K, Okada K, Kimura Y, Seo S, Doki N, Tanaka M, Hatta Y, Takahashi S, Kanda Y; Kanto Study Group for Cell Therapy. Kimura SI, et al. Among authors: hatta y. Bone Marrow Transplant. 2023 Apr;58(4):452-455. doi: 10.1038/s41409-022-01901-5. Epub 2022 Dec 26. Bone Marrow Transplant. 2023. PMID: 36572728 No abstract available.
Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K; Kanto CML Study Group. Yoshida C, et al. Among authors: hatta y. Int J Hematol. 2023 May;117(5):694-705. doi: 10.1007/s12185-023-03549-3. Epub 2023 Feb 4. Int J Hematol. 2023. PMID: 36739328 Free PMC article. Clinical Trial.
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Sato A, et al. Among authors: hatta y. Lancet Haematol. 2023 Jun;10(6):e419-e432. doi: 10.1016/S2352-3026(23)00072-8. Epub 2023 May 8. Lancet Haematol. 2023. PMID: 37167992 Clinical Trial.
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.
Toya T, Mizuno K, Sakurai M, Kato J, Mori T, Doki N, Masuda S, Aotsuka N, Tsukamoto S, Sakaida E, Nakajima Y, Fujisawa S, Machida S, Aoyama Y, Yokoyama H, Shono K, Hatta Y, Usuki K, Kataoka K, Kanda Y. Toya T, et al. Among authors: hatta y. Blood Adv. 2024 Mar 12;8(5):1084-1093. doi: 10.1182/bloodadvances.2023010735. Blood Adv. 2024. PMID: 38330190 Free PMC article.
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
Shimizu H, Kato J, Tanoue S, Kimura SI, Tachibana T, Hatano K, Usuki K, Taguchi J, Hagihara M, Tsukada N, Harada K, Takahashi S, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Handa H, Hatta Y, Nakaseko R, Yano S, Ohashi K, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: hatta y. Leuk Res. 2024 Sep;144:107562. doi: 10.1016/j.leukres.2024.107562. Epub 2024 Aug 20. Leuk Res. 2024. PMID: 39178610
Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O.
Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, Murayama T, Yamazaki E, Sato S, Atsuta Y, Ishikawa Y, Sakaida E, Hatta Y, Matsumura I, Miyazaki Y, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Hayakawa F, et al. Among authors: hatta y. Cancer Sci. 2024 Nov 21. doi: 10.1111/cas.16405. Online ahead of print. Cancer Sci. 2024. PMID: 39572007 Free article.
Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, Tomiyama Y; R788-1301 Investigators. Kuwana M, et al. Among authors: hatta y. Br J Haematol. 2023 Mar;200(6):802-811. doi: 10.1111/bjh.18582. Epub 2022 Dec 5. Br J Haematol. 2023. PMID: 36470677 Clinical Trial.
315 results